Combined transcatheter arterial chemoembolization and beta-ultrasound guided portal vein embolization in the treatment of hepatocellular carcinoma.
- Author:
Guoxin MAO
1
;
Zhijian YU
;
Yixin ZHANG
;
Jianping CHENG
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Aged; Arteries; Carcinoma, Hepatocellular; drug therapy; metabolism; pathology; therapy; Catheterization; Chemoembolization, Therapeutic; adverse effects; methods; Female; Follow-Up Studies; Humans; Liver Neoplasms; drug therapy; metabolism; pathology; therapy; Male; Middle Aged; Portal Vein; Treatment Outcome; alpha-Fetoproteins; metabolism
- From: Chinese Journal of Oncology 2002;24(4):391-393
- CountryChina
- Language:English
-
Abstract:
OBJECTIVETo study the effect of transcatheter arterial chemoembolization (TACE) combined with beta-ultrasound guided portal vein embolization (PVE) through fine-needle liver puncture for hepatocellular carcinoma.
METHODS209 patients with primary hepatocellular carcinoma were divided into TACE group (104 patients) and TACE + PVE group (105 patients).
RESULTSThe response rates (CR + PR) were 37.5% in TACE group and 57.2% in TACE + PVE group (P < 0.01). Tumor thrombi became lessened or resolved in the portal vein with incidences of 22.2% in TACE group and 68.8% in TACE + PVE group (P < 0.01). The 1-, 2- and 3-year survival rates were 65.1%, 36.3% and 20.5% in TACE group and 95.6%, 59.6% and 39.1% in TACE + PVE group (P < 0.05).
CONCLUSIONThe effect of TACE combined with PVE is much more effective than TACE alone for hepatocellular carcinoma. Beta-ultrasound guided portal vein embolization through fine-needle liver puncture is effective, easy, safe and should be widely practiced.
